未登录

T

Thierry Noël

univ. bordeaux and cnrs

H指数:25

被引数:2,038

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fpr1p mediates the synergistic effect of rapamycin or tacrolimus with caspofungin in Clavispora lusitaniae in vitro

Fpr1p介导了在克鲁斯念珠菌中雷帕霉素或他克莫司与卡泊芬净的协同作用（体外）

JAC-Antimicrobial Resistance

IF3.3

2026-05-220

OA

Mucosal passive immunization with monoclonal antibodies targeting Candidalysin and Hyr proteins attenuates vaginal candidiasis in mice

使用靶向Candidalysin和Hyr蛋白的单克隆抗体的黏膜被动免疫可减轻小鼠的阴道念珠菌病

IF5.4

2025-12-311

PRE

Development of monoclonal antibodies in tablet form: A new approach for local delivery

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2024-08-010

PRE

Hexokinase and Glucokinases Are Essential for Fitness and Virulence in the Pathogenic Yeast Candida albicans

FRONTIERS IN MICROBIOLOGY

IF4.5

2019-02-2525

OAAI

A CTG Clade Candida Yeast Genetically Engineered for the Genotype-Phenotype Characterization of Azole Antifungal Resistance in Human-Pathogenic Yeasts

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2018-01-015

OAAI

AFM combined to ATR-FTIR reveals Candida cell wall changes under caspofungin treatment

IF5.1

2017-01-0119

OAAI

Disruption of Protein Mannosylation Affects Candida guilliermondii Cell Wall, Immune Sensing, and Virulence

FRONTIERS IN MICROBIOLOGY

IF4.5

2016-12-0240

OAAI

Deletion of the Uracil Permease Gene Confers Cross-Resistance to 5-Fluorouracil and Azoles in Candida lusitaniae and Highlights Antagonistic Interaction between Fluorinated Nucleotides and Fluconazole

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2014-08-0112

OAAI

Molecular Mechanisms of Resistance to 5-Fluorocytosine in Laboratory Mutants of Candida glabrata

IF2.9

2010-07-0945

PREAI

Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2010-03-0197

OAAI

Nonsense and Missense Mutations in FCY2 and FCY1 Genes Are Responsible for Flucytosine Resistance and Flucytosine-Fluconazole Cross-Resistance in Clinical Isolates of Candida lusitaniae

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2009-07-0138

OAAI

Molecular mechanism of flucytosine resistance in Candida lusitaniae:: Contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2007-01-0175

OAAI

Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to Flucytosine and Fluconazole in Candida lusitaniae

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2005-08-0145

OAAI

Differentiation between atypical isolates of Candida lusitaniae and Candida pulcherrrima by determination of mating type

JOURNAL OF CLINICAL MICROBIOLOGY

IF5.4

2005-03-0114

OAAI

Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates:: Indirect evidence of a fluconazole uptake transporter (vol 47, pg 1275, 2003)

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2003-06-010

OAAI

Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates:: Indirect evidence of a fluconazole uptake transporter

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2003-04-0134

OAAI

Alternative identification test relying upon sexual reproductive abilities of Candida lusitaniae strains isolated from hospitalized patients

JOURNAL OF CLINICAL MICROBIOLOGY

IF5.4

2001-11-0134

OAAI

Development of a colony-blot ELISA assay using monoclonal antibodies to identify Vibrio P1 responsible for ''brown ring disease'': In the clam Tapes philippinarum

IF3.9

1996-11-0111

PREAI